

Maria Vidal

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8134964/maria-vidal-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

67
papers

3,399
citations

24
h-index

58
g-index

74
ext. papers

4,483
ext. citations

8.4
avg, IF

4.14
L-index

#	Paper	IF	Citations
67	Abstract P4-11-28: Collecting quality of life information in a cohort of breast cancer survivors- Integrating electronic data collection into clinical practice. <i>Cancer Research</i> , 2022 , 82, P4-11-28-P4-11-28 ^{10.1}	10.1	0
66	Abstract OT2-11-07: Solti-1905. Elacestrant in preoperative setting, a window of opportunity study (ELIPSE trial). <i>Cancer Research</i> , 2022 , 82, OT2-11-07-OT2-11-07	10.1	0
65	Abstract OT2-27-01: Solti-1718 NEREA Trial: Neratinib in hormone receptor (HR)-positive/HER2-negative HER2-enriched (HER2-E) advanced breast cancer (BC). <i>Cancer Research</i> , 2022 , 82, OT2-27-01-OT2-27-01	10.1	0
64	Abstract P2-14-13: Talimogene laherparepvec (T-VEC) + atezolizumab combination in early breast cancer (SOLTI-1503 PROMETEO): Safety and efficacy interim analysis. <i>Cancer Research</i> , 2022 , 82, P2-14-13-P2-14-13 ^{10.1}	10.1	0
63	Abstract P4-07-08: Prognostic value of intrinsic subtypes (IS) in hormone receptor-positive (HoR+) metastatic breast cancer (MBC): A systematic review and meta-analysis of prospective trials. <i>Cancer Research</i> , 2022 , 82, P4-07-08-P4-07-08	10.1	0
62	Assessment of the management of carcinomatous meningitis from breast cancer globally: a study by the Breast International Group Brain Metastasis Task Force.. <i>ESMO Open</i> , 2022 , 7, 100483	6	1
61	First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study. <i>Frontiers in Oncology</i> , 2021 , 11, 744112	5.3	2
60	Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer. <i>Npj Precision Oncology</i> , 2021 , 5, 23	9.8	5
59	Genetic profiling across multiple cancer types using molecular prescreening comprehensive gene panels offered by clinical trials (CT).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3060-3060	2.2	
58	Gene expression profiles of breast cancer metastasis according to organ site. <i>Molecular Oncology</i> , 2021 ,	7.9	3
57	Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. <i>Npj Breast Cancer</i> , 2021 , 7, 1	7.8	54
56	Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy. <i>Clinical Cancer Research</i> , 2021 , 27, 3116-3125	12.9	3
55	Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy. <i>Npj Breast Cancer</i> , 2021 , 7, 8	7.8	2
54	Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy. <i>EBioMedicine</i> , 2021 , 69, 103451	8.8	3
53	Frequency and spectrum of PIK3CA somatic mutations in breast cancer. <i>Breast Cancer Research</i> , 2020 , 22, 45	8.3	55
52	SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer. <i>Future Oncology</i> , 2020 , 16, 1801-1813	3.6	4
51	Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Phase 1 and Randomized Phase 2 Trial. <i>JAMA Oncology</i> , 2020 , 6, 1203-1209	13.4	4

50	HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2020 , 84, 101965	14.4	39
49	Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade. <i>Nature Communications</i> , 2020 , 11, 385	17.4	36
48	Clinical activity of MCLA-128 (zenocutuzumab) in combination with endocrine therapy (ET) in ER+/HER2-low, non-amplified metastatic breast cancer (MBC) patients (pts) with ET-resistant disease who had progressed on a CDK4/6 inhibitor (CDK4/6i).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1037-1037	2.2	10
47	Methodological guidelines for preparing a structured therapeutic education program: From design to evaluation. <i>Revista Clinica Espanola</i> , 2020 , 221, 448-448	0.7	1
46	mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer. <i>Cancers</i> , 2020 , 12,	6.6	9
45	Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial. <i>Cancers</i> , 2020 , 12,	6.6	2
44	A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. <i>Lancet Oncology, The</i> , 2020 , 21, 1455-1464	21.7	20
43	A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor-positive HER2-negative Breast Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 6141-6148	12.9	2
42	HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. <i>Journal of the National Cancer Institute</i> , 2020 , 112, 46-54	9.7	48
41	Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial. <i>Breast Cancer Research</i> , 2019 , 21, 108	8.3	11
40	Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication. <i>Therapeutic Advances in Medical Oncology</i> , 2019 , 11, 1758835919833867	5.4	23
39	A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2019 , 9, 303	5.3	3
38	Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2. <i>Oncologist</i> , 2019 , 24, 893-900	5.7	12
37	Antibodies to M-type phospholipase A2 receptor (PLAR) in membranous lupus nephritis. <i>Lupus</i> , 2019 , 28, 396-405	2.6	17
36	Significant Clinical Activity of Olaparib in a Somatic BRCA1-Mutated Triple-Negative Breast Cancer With Brain Metastasis.. <i>JCO Precision Oncology</i> , 2019 , 3, 1-6	3.6	4
35	A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial. <i>Annals of Oncology</i> , 2018 , 29, 661-668	10.3	6
34	A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CeTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade. <i>Annals of Oncology</i> , 2018 , 29, 170-177	10.3	45
33	Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types. <i>Annals of Oncology</i> , 2018 , 29, 2121-2128	10.3	41

32	PAM50 intrinsic subtype in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with exemestane (EXE) in combination with everolimus (EVE) or placebo (PBO): A correlative analysis of the phase III BOLERO-2 trial. <i>European Journal of Cancer</i> , 2018 , 20, 3117-3118	7.5	3
31	PAM50 HER2-enriched/ERBB2-high (HER2-E/ERBB2H) biomarker to predict response and survival following lapatinib (L) alone or in combination with trastuzumab (T) in HER2+ T-refractory metastatic breast cancer (BC): A correlative analysis of the EGF104900 phase III trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1005-1007	2.2	2
30	Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIB BALLET trial in Spain. <i>Clinical and Translational Oncology</i> , 2018 , 20, 753-760	3.6	5
29	A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation. <i>EMBO Molecular Medicine</i> , 2018 , 10,	12	85
28	HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 545-554	21.7	175
27	Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer. <i>Cancer Research</i> , 2017 , 77, 2213-2221	10.1	109
26	Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer. <i>Oncotarget</i> , 2017 , 8, 21930-21937	3.3	10
25	Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay. <i>Clinical Cancer Research</i> , 2016 , 22, 560-6	12.9	57
24	Molecular Classification of Breast Cancer 2016 , 203-219		0
23	A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparable Toxicity (PROTECT-2). <i>Phase III Randomized Double-Blind Trial</i>	5.7	32
22	Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer. <i>Current Medical Research and Opinion</i> , 2015 , 31, 1129-37	2.5	25
21	Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy. <i>BMC Medicine</i> , 2015 , 13, 303	11.4	87
20	Gene expression-based classifications of fibroadenomas and phyllodes tumours of the breast. <i>Molecular Oncology</i> , 2015 , 9, 1081-90	7.9	25
19	Association of BRCA1 germline mutations in young onset triple-negative breast cancer (TNBC). <i>Clinical and Translational Oncology</i> , 2014 , 16, 280-4	3.6	20
18	Predicting response and survival in chemotherapy-treated triple-negative breast cancer. <i>British Journal of Cancer</i> , 2014 , 111, 1532-41	8.7	82
17	Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer. <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	132
16	Trastuzumab emtansine (T-DM1) plus capecitabine (X) in patients with HER2-positive MBC: MO28230 TRAX-HER2 phase 1 results.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 606-606	2.2	2
15	Management of the axilla in early breast cancer patients in the genomic era. <i>Annals of Oncology</i> , 2013 , 24, 1163-70	10.3	7

14	Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity. <i>Scientific Reports</i> , 2013 , 3, 3544	4.9	42
13	PAM50 HER2-enriched (HER2E) phenotype as a predictor of early-response to neoadjuvant lapatinib plus trastuzumab in stage I to IIIA HER2-positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, TPS665-TPS665	2.2	
12	Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis. <i>Annals of Oncology</i> , 2012 , 23, 1130-1137	10.3	54
11	Beyond taxanes: the next generation of microtubule-targeting agents. <i>Breast Cancer Research and Treatment</i> , 2012 , 133, 821-30	4.4	40
10	Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. <i>Annals of Oncology</i> , 2012 , 23, 897-902	10.3	107
9	PI3K pathway (PI3Kp) dysregulation and response to pan-PI3K/AKT/mTOR/dual PI3K-mTOR inhibitors (PI3Kpi) in metastatic breast cancer (MBC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 509-509	2.2	3
8	Presentation and treatment of HER2-positive metastatic breast cancer patients already treated with adjuvant trastuzumab.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 619-619	2.2	
7	Prognostic significance of PI3K pathway (PI3Kp) dysregulation in metastatic breast cancer (MBC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 566-566	2.2	
6	HER2 and hormone receptor-positive breast cancer--blocking the right target. <i>Nature Reviews Clinical Oncology</i> , 2011 , 8, 307-11	19.4	24
5	Lung carcinosarcoma. <i>Clinical and Translational Oncology</i> , 2010 , 12, 303-5	3.6	8
4	Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. <i>Nature Genetics</i> , 2009 , 41, 221-7	36.3	509
3	A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. <i>Nature</i> , 2008 , 452, 638-642	50.4	1239
2	Prognostic significance and diagnostic value of protein S-100 and tyrosinase in patients with malignant melanoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2008 , 31, 335-9	2.7	12
1	Therapeutic education seminars for patients with type 1 diabetes and their relatives. <i>European Diabetes Nursing</i> , 2006 , 3, 132-136		0